Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001

Publisher： Karger

E-ISSN： 1662-6575|9|1|164-170

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.9, Iss.1, 2016-03, pp. : 164-170

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

By  

Case Reports in Oncology, Vol. 8, Iss. 3, 2015-10 ,pp. : 461-465

Karger

Access to resources Recommend Favorite

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-01 ,pp. : 45-50

Karger

Access to resources Recommend Favorite

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor

By  

Case Reports in Oncology, Vol. 10, Iss. 1, 2017-03 ,pp. : 276-280

Karger

Access to resources Recommend Favorite

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets

By  

Case Reports in Oncology, Vol. 9, Iss. 2, 2016-05 ,pp. : 285-289

Karger

Access to resources Recommend Favorite

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-01 ,pp. : 79-85

Karger

Access to resources Recommend Favorite